A Phase 1 interventional study of AZD4954 and Laroprovstat in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing laroprovstat in Dyslipidemias — none open to participants now, 1 under way, 1 of them phase 3. laroprovstat · Dyslipidemias.
Among the 11 studies testing laroprovstat in Dyslipidemias, this one is the 8th largest by enrollment, is one of 2 that started in 2026, is one of 8 in phase 1, and was the 11th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 11 studies testing laroprovstat in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 1
First in 2022; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 59 across the 11 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
57 studies in Dyslipidemias by AstraZeneca: 1 open now, 3 under way, 1 of them phase 3. Of 52 finished, 11 (21%) have results posted.
Among the 57 studies in Dyslipidemias by AstraZeneca, this one is the 30th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2026, is one of 16 in phase 1, and was the 56th registered.
AstraZeneca’s Dyslipidemias studies by the year they started, since 2002.
1 of the studies testing laroprovstat in Dyslipidemias that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06834932Phase 3AstraZenecaA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | 2027-02-22 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing laroprovstat in Dyslipidemias, from their registry updates:
Among AstraZeneca’s 57 in Dyslipidemias:
This tab as a report to print or save as PDF → With an account.
The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.
This is an open-label, fixed-sequence, 2 period and 2 cohort study in healthy participants.
Each participant in each cohort will receive treatments in a fixed order during the 2 treatment periods as follows:
The following treatments will be given during the study:
The study will comprise of a Screening Period, two Treatment Periods and follow-up visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will receive single dose of AZD4954 alone (Treatment A) followed by single doses of laroprovstat+AZD4954 (Treatment C).
Drug: AZD4954 · Drug: Laroprovstat
Participant will receive single dose of laroprovstat alone (Treatment B) followed by single doses of laroprovstat+AZD4954 (Treatment C).
Drug: AZD4954 · Drug: Laroprovstat
AZD4954 will be administered orally.
Laroprovstat will be administered orally.
Also known as: AZD0780
Area under concentration time curve from time 0 to infinity (AUCinf) of AZD4954
To assess the effect of a single dose of oral laroprovstat on the PK of a single dose of oral AZD4954 in healthy participants.
Time frame: Cohort 1: Day 1 to Day 41
Maximum observed drug concentration (Cmax) of AZD4954
To assess the effect of a single dose of oral laroprovstat on the PK of a single dose of oral AZD4954 in healthy participants.
Time frame: Cohort 1: Day 1 to Day 41
AUCinf of laroprovstat
To assess the effect of a single dose of oral AZD4954 on the PK of a single dose of oral laroprovstat in healthy participants.
Time frame: Cohort 2: Day 1 to Day 25
Cmax of laroprovstat
To assess the effect of a single dose of oral AZD4954 on the PK of a single dose of oral laroprovstat in healthy participants.
Time frame: Cohort 2: Day 1 to Day 25
Area under concentration curve from time 0 to the last quantifiable concentration (AUClast) of AZD4954
To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.
Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31
Apparent total body clearance (CL/F) of AZD4954
To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.
Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31
Terminal elimination half-life (t½λz) of AZD4954
To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.
Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31
Time to reach maximum observed concentration (tmax) of AZD4954
To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.
Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31
Time of last quantifiable concentration (tlast) of AZD4954
To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.
Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31
Time delay between drug administration and the first observed concentration (tlag) of AZD4954
To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.
Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31
Apparent volume of distribution based on the terminal phase (Vz/F) of AZD4954
To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.
Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31
AUClast of laroprovstat
To describe the PK of laroprovstat when administered alone and in combination with AZD4954.
Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25
CL/F of laroprovstat
To describe the PK of laroprovstat when administered alone and in combination with AZD4954.
Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25
t½λz of laroprovstat
To describe the PK of laroprovstat when administered alone and in combination with AZD4954.
Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25
tmax of laroprovstat
To describe the PK of laroprovstat when administered alone and in combination with AZD4954.
Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25
tlast of laroprovstat
To describe the PK of laroprovstat when administered alone and in combination with AZD4954.
Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25
tlag of laroprovstat
To describe the PK of laroprovstat when administered alone and in combination with AZD4954.
Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25
Vz/F of laroprovstat
To describe the PK of laroprovstat when administered alone and in combination with AZD4954.
Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
To assess the safety and tolerability of AZD4954 alone and in combination with laroprovstat; and safety and tolerability of laroprovstat alone and in combination with AZD4954 following oral administration of single doses in healthy participants.
Time frame: Cohort 1: Up to Day 83; Cohort 2: Up to Day 73
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Jul 2026, 2 months.
Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 2 months is close to that.
Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: AZD4954 · Laroprovstat